Biocon Share News - Latest Updates, Live News & More

More news about Biocon

Biocon to host Macquarie's Healthcare Tour plant visit on June 11

Biocon Limited will host a plant visit for Macquarie's Healthcare Tour on June 11, 2026, in Bangalore, serving as a group interaction with analysts and institutional investors. The company stated that the schedule is subject to change due to exigencies on the part of investors or the company. The management confirmed that no unpublished price sensitive information (UPSI) will be disclosed during the meeting.

09Jun 26

Biocon approves CEO appointment and remuneration revisions

Biocon Limited shareholders approved ten resolutions via postal ballot, including the appointment of Shreehas Pradeep Tambe as CEO & MD and remuneration revisions for Kiran Mazumdar-Shaw. The voting, held from May 09 to June 07, 2026, saw 73.56% participation and approved the preferential issuance of equity shares and several director appointments.

02Jun 26

Biocon reduces net debt to EBITDA ratio by 1.6x

Biocon Limited reduced its net debt to EBITDA ratio by 1.6x following a strategic refinancing that lowered total debt to $1,348 million from $1,389 million. The new debt structure defers major maturities to FY28 and FY29, enhancing liquidity. Additionally, the company increased its stake in Biocon Biologics to 99.2% and completed major infrastructure investments.

31May 26

Biocon revises preferential issue price to ₹376.41 per share

Biocon Limited revised the pricing for its preferential issue to ₹376.41 per share, with a floor price of ₹373.08, following advice from NSE and BSE. The company will issue 87,86,362 shares to Biocon Biologics shareholders at a swap ratio of 0.76159. A corrigendum was dispatched on May 29, 2026, and advertised in newspapers on May 30, 2026, with voting concluding on June 07, 2026.

28May 26

Biocon to meet investors at Investec US Pharma event on June 3

Biocon announced that its management will meet analysts and institutional investors on June 3, 2026, at the Investec US Pharma & Healthcare Bus Tour in the USA. The company stated that no unpublished price sensitive information will be disclosed during the meeting, which is subject to change due to exigencies.

27May 26

Biocon Records Rs. 17.37 Crore Block Trade on NSE at Rs. 431.95 Per Share

Biocon recorded a block trade on the NSE involving approximately 402,121 shares at Rs. 431.95 per share. The total value of the transaction amounted to Rs. 17.37 crores. Block trades of this scale are typically associated with institutional-level participation and are executed to minimize market impact.

11May 26

Biocon Pharma Limited Receives Health Canada Approval for Micafungin for Injection, USP, 50 MG and 100 MG

Biocon Pharma Limited, a subsidiary of Biocon Limited, received Health Canada approval on May 11, 2026, for micafungin for injection, USP, 50 mg and 100 mg. The product is indicated for adults and children four months and older for the treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections, esophageal candidiasis, and prophylaxis of Candida infections in hematopoietic stem cell transplant patients. The approval is set to further strengthen Biocon's integrated biosimilars and generics portfolio.

10May 26

Biocon Q4FY26 & FY26 Results: Revenue Up 10% YoY; Key Corporate Actions Approved

Biocon reported Q4FY26 operating revenue of Rs 4,517 Cr and FY26 revenue of Rs 16,927 Cr, both up ~10-13% YoY on an adjusted basis, with EBITDA margin expanding ~200 bps. The Board approved the acquisition of remaining ~2% BBL equity via share swap at Rs. 376.16/share, a final dividend of Re. 0.50/share, new auditors, and an LTIP. The audio and video recording of the Q4 FY26 Earnings Call held on May 08, 2026 has been made available pursuant to SEBI Regulation 30.

08May 26

Biocon Approves Preferential Allotment to Consolidate Stake in Biocon Biologics

Biocon has approved the acquisition of approximately 2% stake in Biocon Biologics from employees and other shareholders via a preferential allotment. The company will issue up to 87.9 lakh shares at ₹376.16 each, aggregating to approximately ₹330.7 crore. The transaction is subject to requisite approvals and is intended to consolidate Biocon's ownership in its subsidiary Biocon Biologics.

05May 26

Kiran Mazumdar-Shaw Names Niece Claire Mazumdaar as Her Successor at Biocon

Biocon founder Kiran Mazumdar-Shaw has named her niece Claire Mazumdaar as her successor, as reported by Reuters citing Fortune India. The announcement signals a planned leadership transition at the biopharmaceutical company. No further specifics regarding the timeline or scope of the transition were available in the source data.

05May 26

Biocon Anticipates Margin Pressure for Insulin Glargine

Biocon has signaled anticipated margin pressure for its Insulin Glargine product, as reported by NDTV. The disclosure highlights potential challenges in the profitability of this biosimilar within the company's portfolio. No specific financial figures or timeframes were included in the available source information.

01May 26

Biocon: U.S. FDA Completes Pre-License Inspection At Biosimilars Plant

Biocon Limited successfully completed a U.S. FDA Pre-License Inspection at its biosimilars manufacturing facility in Bengaluru from April 20-29, 2026. The inspection covered 3 biologics manufacturing units, 5 quality testing laboratories, and 2 warehouses. The FDA issued a Form 483 with five procedural observations, notably with no data integrity issues or repeat observations from previous inspections. The company filed an official statement with stock exchanges on April 30, 2026, and committed to addressing all observations through a comprehensive CAPA plan within the FDA's stipulated timeline.

29Apr 26

Biocon Limited Publishes Newspaper Advertisements for Second 100 Days Campaign 'Saksham Niveshak'

Biocon Limited published newspaper advertisements on April 28, 2026, in Financial Express and Vijayavani as part of the Second 100 Days Campaign 'Saksham Niveshak' launched by the IEPF Authority. The campaign aims to help shareholders update KYC and bank details to claim unpaid/unclaimed dividends before transfer to IEPF. The company has submitted advertisement copies to BSE and NSE under SEBI regulatory compliance requirements.

26Apr 26

Biocon Limited Board Meeting intimation for Q4FY26 under Regulation 29 scheduled on 2026-05-07

Biocon Limited has filed regulatory intimation under SEBI LODR Regulation 29(1) for board meeting on May 07, 2026 to approve audited Q4 and FY26 financial results. The company has implemented trading window closure from April 01-May 09, 2026 for insider trading compliance. An earnings conference call is scheduled for May 08, 2026 at 09:00 hrs IST via Zoom, with recordings and transcripts to be made available within specified timelines.

22Apr 26

Biocon Receives Health Canada Approval for Biosimilars Bosaya and Vevzuo

Biocon Limited announced Health Canada's approval of Bosaya™ and Vevzuo™, denosumab biosimilars for treating osteoporosis and cancer-related bone conditions. The approval covers multiple patient populations including postmenopausal women, men with osteoporosis, and cancer patients with bone metastases, potentially benefiting over 2 million adults with osteoporosis and hundreds with bone metastasis annually.

22Apr 26

Biocon Limited Issues KYC Compliance Reminder to Physical Shareholders Under SEBI Regulations

Biocon Limited has issued a compliance reminder to physical shareholders regarding mandatory KYC updates as per SEBI Master Circular dated February 06, 2026. The company warns that dividend payments may be withheld for non-compliant folios and has outlined specific documentation requirements including Form ISR-1 and Form ISR-2 submissions through multiple channels including courier, electronic mode, or web portal via registrar KFin Technologies Limited.

20Apr 26

HSBC Maintains Buy Rating on Biocon with ₹425 Target Price on Strong Growth Foundation

HSBC has reaffirmed its Buy rating on Biocon with a target price of ₹425, highlighting the company's strengthened foundation through debt reduction and corporate simplification. The investment bank identifies execution of new biosimilar launches, improving profitability metrics, enhanced cash flow generation, and market share gains in biosimilars as key growth catalysts for the biotechnology company.

08Apr 26

Biocon Limited Schedules Investor Meetings at HSBC Global Investment Summit 2026 and Singapore Roadshow

Biocon Limited has scheduled investor meetings at the HSBC Global Investment Summit 2026 in Hong Kong on April 14-15, 2026, and an investor roadshow in Singapore on April 16-17, 2026. The company will conduct one-on-one and group meetings with analysts and institutional investors while ensuring no unpublished price sensitive information is disclosed during these interactions.

08Apr 26

Biocon Limited Submits Q4 FY26 Certificate Under SEBI Depositories Regulations

Biocon Limited filed its mandatory quarterly certificate under SEBI Regulation 74(5) for Q4 FY26 on April 07, 2026, covering the quarter ended March 31, 2026. The certificate confirms compliance with dematerialization and rematerialization requirements, with registrar KFin Technologies Limited providing confirmation of proper handling of all demat processes including timely request processing and register maintenance.

08Apr 26

Biocon Announces U.S. Launch Of Bosaya™ And Aukelso™ Denosumab Biosimilars

Biocon Limited has commercially launched two denosumab biosimilars, Bosaya™ and Aukelso™, in the United States following FDA approval with interchangeable designation. These products target significant patient populations with osteoporosis and bone metastasis, entering a $5 billion market segment while expanding Biocon's biosimilars portfolio in oncology and immunology therapeutics.

07Apr 26

Biocon Ltd Records ₹47.97 Crore Block Trade on NSE at ₹349.00 Per Share

Biocon Ltd witnessed significant institutional trading activity with a block trade worth ₹47.97 crores on NSE. The transaction involved approximately 1,374,453 shares priced at ₹349.00 per share, reflecting routine institutional portfolio adjustments and demonstrating strong liquidity in the company's stock.